華映科技(000536.SZ):控股子公司收到增值税留抵退税13.31億元
格隆匯6月17日丨華映科技(000536.SZ)公佈,公司控股子公司福建華佳彩有限公司(“華佳彩”)依據《財政部税務總局關於進一步加大增值税期末留抵退税政策實施力度的公吿》(財政部税務總局公吿2022年第14號)的相關要求,向主管税務機關提出增值税退税申請,經税務機關審核,准予退還增值税留抵税額人民幣1,331,158,142.04元。華佳彩銀行賬户於2022年6月17日收到該筆退税款。
根據企業會計準則相關規定,該增值税期末留抵税額的退還將對公司現金流產生積極影響,對公司的損益不產生直接影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.